A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 114 participants.

Also called NCT02210000

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 114 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02210000
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02210000. Randomized; double masking; primary purpose treatment. Start 2014-08-27 (actual); primary completion 2015-08-24 (actual). Results posted on 2017-11-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Condition
Gastroparesis
Intervention (Drug)
Placebo
Intervention (Drug)
Camicinal
Lead sponsor
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct02210000
Content hash
30d2edca3b6e77b437477fab1dcbff010f1854613953e46c110a5f22d9837daa